Litigation Details for Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. (D. Del. 2021)
✉ Email this page to a colleague
Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. (D. Del. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-12-21 |
| Court | District Court, D. Delaware | Date Terminated | 2024-03-13 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Patents | 10,016,435; 9,439,906 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Janssen Pharmaceuticals, Inc. v. Tolmar, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Janssen Pharmaceuticals, Inc. v. Tolmar, Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-09-08 | 114 | Order - Memorandum and Order AND ~Util - Terminate Motions | U.S. Patent No. 9,439,906 (“the ’906 patent”) against Tolmar in this action. The ’906 patent is generally…loading dose. ’906 patent, cl. 1. On its face, the ’906 patent claims priority to one …applicant for a patent.” Accordingly, the key question is whether the claims of the ’906 patent are entitled…AND ORDER In this Hatch-Waxman Act patent case, plaintiffs Janssen Pharmaceuticals Inc. and…dispute the priority date of the claims of the ’906 patent. For purposes of the present motion, claim | External link to document |
| 2023-09-25 | 124 | In Limine | Other Litigation Proceedings Regarding U.S. Patent No. 9,439,906 - filed by Tolmar, Inc.. (Poff, Adam) (Entered…2021 13 March 2024 1:21-cv-01784 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-09-25 | 125 | Exhibit to a Document | Other Litigation Proceedings Regarding U.S. Patent No. 9,439,906 by Tolmar, Inc.. (Attachments: # 1 Declaration…2021 13 March 2024 1:21-cv-01784 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-10-08 | 137 | Statement | Janssen’s U.S. Patent No. 9,439,906 (the “’906 patent”) (JTX-1). The ’906 patent is directed to…INVENTIONS OF THE ’906 PATENT The dosing regimens claimed in the ’906 patent recite a specific …3176 that issued as U.S. Patent No. 6,555,544, the “’544 patent” (one of the references Tolmar’…the ’544 patent are described as effective for three weeks to a month, and the ’544 patent taught that… of claims 17-21 of the ’906 patent are not obvious. The ’544 patent disclosed an upper limit to a | External link to document |
| 2023-10-08 | 138 | Statement | shoulder. The patent-in-suit, U.S. Patent No. 9,439,906 (“the ’906 patent”) is a method of treatment…the features of the ’906 patent. The ’906 patent. The ’906 patent was filed December 17, 2008…including the ’544 patent, U.S. Patent No. 5,254,556, and U.S. Patent No. 6,077,843. Remaining…last patent in a long line of patents that Janssen has listed in the Orange Book for Invega Sustenna…few weeks before the ’906 patent on December 5, 2008. The ’906 patent is directed to a method | External link to document |
| 2023-12-05 | 143 | Redacted Document | because of modesty concerns. Day 1 Tr. 370:10-16, 435:2-437:1, 438:6-10; JTX-030; JTX-032; JTX-…obviated by blocking patents, such as the ‘556 patent, the ‘843 patent, and the ‘544 patent. Where practice… ‘544 patent JTX-020 U.S. Patent No. 6,555,544 to Francois et al. ‘556 patent …DTX-433 U.S. Patent No. 5,254,556 ‘843 patent DTX-434 U.S. Patent No. 6,077,843 A …infringe an earlier patent, the earlier patent has been called a “blocking patent.” Acorda Therapeutics | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
